mc_090612020-2081349099-O copy 2
GALECTIN THERAPEUTICS

Pioneers In Galectin Science & Drug Development

Galectin Therapeutics (NASDAQ: GALT), a development stage company, is the world’s leading developer of therapeutics targeting galectin proteins to treat chronic liver and skin diseases and cancer.

Headquartered in the burgeoning biotech center of Atlanta, Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis, including multiple inflammatory, fibrotic, and malignant diseases. The Company's lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH-related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. The Company has additional development programs in the treatment of severe atopic dermatitis, moderate-to-severe plaque psoriasis, and in combination immunotherapy for advanced melanoma and other malignancies.

In 2009, 10X Capital led the takeover and restructuring of the Company, which at the time was on the brink of bankruptcy. As a result, the Company was recapitalized (at 500% above market to avoid unnecessary dilution of the then-existing shareholders); a world-class leadership team was brought in, including GlaxoSmithKline's former head of global drug development, a former Apple CEO, and other key leaders; and, in 2012, the Company was listed on the NASDAQ. In addition to his leadership duties through 10X Capital, Rod Martin took hands-on leadership at Galectin for six years as Vice Chairman, and simultaneously as Chairman of the Company's Nominating and Corporate Governance Committee and its Compensation Committee.

The U.S. Food and Drug Administration has granted Galectin's NASH liver fibrosis drug Fast Track status, and in December 2017, that drug successfully completed its Phase II clinical trial. In May 2018, the FDA approved its Phase III trial design and granted permission to go forward with the trial. That same month, the Company elected self-made billionaire and prominent shareholder (at Galectin and 10X) Richard E. Uihlein chairman of its board.

"Having been on the other side of the table, I don’t believe our deal with the 10X Fund would have been possible without Rod’s leadership and negotiating skill."


Steve Prelack

Former Director and Audit Committee Chairman
Galectin Therapeutics